Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23 USD | +0.26% | +8.44% | +32.41% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 446.8 | 528.5 | 452.6 | 527.7 | 843.8 | - | - |
Enterprise Value (EV) 2 | 409.3 | 454.9 | 452.6 | 473.9 | 752 | 759.6 | 809.9 |
P/E ratio | -13.4 x | -13.7 x | -9.99 x | -11.6 x | -59 x | -34.4 x | -32.4 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 81.5 x | 42.6 x | 25.9 x | 20.8 x | 33.7 x | 27 x | 31.3 x |
EV / Revenue | 74.7 x | 36.6 x | 25.9 x | 18.7 x | 30 x | 24.3 x | 30.1 x |
EV / EBITDA | -11.6 x | -10 x | -9.41 x | - | -12.5 x | -117 x | -11.2 x |
EV / FCF | -36.3 x | 420 x | -9.93 x | - | -13.4 x | -8.77 x | -7.97 x |
FCF Yield | -2.76% | 0.24% | -10.1% | - | -7.47% | -11.4% | -12.5% |
Price to Book | - | - | - | - | 37.3 x | 37.3 x | 331 x |
Nbr of stocks (in thousands) | 27,769 | 29,928 | 35,893 | 38,670 | 46,615 | - | - |
Reference price 3 | 22.00 | 23.89 | 15.25 | 17.37 | 23.00 | 23.00 | 23.00 |
Announcement Date | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 0.244 | 5.479 | 12.42 | 17.5 | 25.38 | 25.05 | 31.24 | 26.92 |
EBITDA 1 | -22.25 | -35.35 | -45.39 | -48.11 | - | -59.96 | -6.467 | -72.27 |
EBIT 1 | -22.73 | -35.85 | -45.81 | -48.59 | -49.6 | -50.75 | -55.65 | -81.42 |
Operating Margin | -9,317.21% | -654.26% | -369.02% | -277.66% | -195.48% | -202.62% | -178.15% | -302.43% |
Earnings before Tax (EBT) 1 | -22.87 | -36.04 | -45.86 | -47.37 | -50.31 | -44.52 | -76.83 | -89.47 |
Net income 1 | -19.58 | -32.55 | -39.41 | -40.49 | -43.27 | -40.63 | -73.63 | -86.27 |
Net margin | -8,025.41% | -594.03% | -317.44% | -231.35% | -170.51% | -162.19% | -235.74% | -320.45% |
EPS 2 | - | -1.638 | -1.742 | -1.527 | -1.491 | -0.3896 | -0.6682 | -0.7090 |
Free Cash Flow 1 | - | -11.29 | 1.084 | -45.6 | - | -56.2 | -86.6 | -101.6 |
FCF margin | - | -206% | 8.73% | -260.53% | - | -224.36% | -277.25% | -377.37% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 4/14/20 | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 1.146 | 4.333 | 5.845 | 3.156 | 3.414 | 6.57 | 5.722 | 3.643 | 9.365 | 3.371 | 4.765 | 8.136 | 11.37 | 9.104 | 2.798 | 2.099 | 12.41 | 9.85 | 3.6 | 3.6 | 3.55 |
EBITDA | -13.98 | - | -22.02 | - | - | - | -9.21 | -13.98 | - | -13.51 | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -14.19 | -21.65 | -22.27 | -12.28 | -11.26 | -23.55 | -9.922 | -14.09 | -24.01 | -13.62 | -10.96 | -24.58 | -12.15 | -11.46 | -12.7 | -13.3 | -4.156 | -13.6 | -14.7 | -15.8 | - |
Operating Margin | -1,238.48% | -499.75% | -380.98% | -389.23% | -329.91% | -358.39% | -173.4% | -386.74% | -256.39% | -404.06% | -230.03% | -302.14% | -106.81% | -125.85% | -453.86% | -633.59% | -33.5% | -138.07% | -408.33% | -438.89% | - |
Earnings before Tax (EBT) 1 | -13.33 | -22.71 | -22.58 | -12.05 | -11.23 | -23.28 | -9.572 | -13.42 | -22.99 | -9.326 | -15.05 | -24.38 | -12.67 | -12.01 | -10.66 | -14.97 | -3.365 | -13.6 | -14.7 | -15.8 | - |
Net income 1 | -11.03 | -21.52 | -20.05 | -9.929 | -9.434 | -19.36 | -7.684 | -11.94 | -19.62 | -7.103 | -20.64 | -27.74 | -10.2 | -10.4 | -8.25 | -14.41 | -1.876 | -12 | -13.1 | -14.2 | - |
Net margin | -962.39% | -496.61% | -342.99% | -314.61% | -276.33% | -294.7% | -134.29% | -327.72% | -209.54% | -210.71% | -433.2% | -341.02% | -89.71% | -114.25% | -294.85% | -686.61% | -15.12% | -121.83% | -363.89% | -394.44% | - |
EPS 2 | - | -1.070 | -0.9462 | - | - | -0.8452 | - | -0.4873 | -0.8024 | - | -0.4775 | -0.7290 | -0.3559 | -0.3668 | -0.2722 | -0.4792 | -0.0532 | -0.0939 | -0.1299 | -0.1343 | -0.1394 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 9/14/20 | 3/30/21 | 8/12/21 | 11/16/21 | 3/17/22 | 3/17/22 | 5/16/22 | 8/11/22 | 8/11/22 | 11/10/22 | 3/15/23 | 3/15/23 | 5/16/23 | 8/16/23 | 11/14/23 | 3/13/24 | 5/16/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 13.5 | 37.4 | 73.5 | - | 53.8 | 91.9 | 84.3 | 33.9 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -11.3 | 1.08 | -45.6 | - | -56.2 | -86.6 | -102 |
ROE (net income / shareholders' equity) | - | -359% | -448% | - | - | -149% | -8.31% | -188% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | - | 0.6200 | 0.6200 | 0.0700 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.01 | 0.51 | 1.31 | 0.14 | - | 1.5 | 10 | 20 |
Capex / Sales | 3.69% | 9.33% | 10.56% | 0.8% | - | 5.99% | 32.02% | 74.29% |
Announcement Date | 4/14/20 | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
- Stock Market
- Equities
- SLN Stock
- Financials Silence Therapeutics plc